STRATEGIC R&D LEADER AND HYBRID SCIENTIST
Multidisciplinary PhD Immunologist with over 15 years of leadership in biotech R&D. I orchestrate the full drug development value chain, spanning high-level academic discovery, cross-border corporate transformations, and late-phase clinical transitions.
I bridge the gap between biological complexity and computational integrity by leveraging applied AI, machine learning, and IT-grade biostatistics. My mission is to accelerate the discovery of next-generation therapeutics—across vaccines, biologics, and small molecules—by integrating version-controlled transparency and reproducible workflows into rigorous scientific and regulatory standards.
CORE STRATEGIC PHILOSOPHY
- Multi-Modality Expertise: Proven track record in the development of DNA vaccines, small molecules, peptides, and complex biologics (bispecifics, immunocytokines)
- Diverse Therapeutic Impact: Extensive R&D experience across immuno-oncology, allergy, autoimmune diseases, inflammatory disorders, and infectious diseases
- Agile Research Settings: Successfully led programs within Big Pharma (Roche), high-growth Biotech (VAXIMM, Worg), prestigious Academic Institutes (Ludwig, CNRS), and specialized R&D Consulting
- Computational Integrity: Architect of high-integrity Python pipelines designed to replace manual data processing with reproducible, auditable, and version-controlled discovery workflows
- Scientific Authorship: Author of the forthcoming book "Intuitive Biostatistics with Python" (Oxford University Press, 2026), establishing a new standard for data literacy in the life sciences
RESEARCH EXPERIENCE
- Leading a multi-modality R&D strategy focused on platform innovation and the integration of translational programs into global regulatory milestones
- Safeguarding IP assets and directing capital strategy to stabilize R&D during complex global transitions
executive leadership
crisis management
global regulatory strategy
immuno-oncology
- Provided essential technical oversight and R&D stabilization during the successful public market transition
- Oversaw the CMC and Quality strategy for live biotherapeutics, including the design of innovative oral formulations for DNA vaccines
- Managed a global network of internal teams and decentralized CROs/CDMOs to ensure preclinical and translational integrity through rigorous data standards
DNA vaccines
immunotherapy
translational R&D
CRO/CDMO management
oral formulation
- Developed a comprehensive educational resource aligning statistical simulations with modern Python-based discovery for life science professionals
- Created a public library of reusable, documented code templates to facilitate reproducible research and advanced scientific visualization
biostatistics
Python
data science
teaching
professional editorial work
reproducible code
- Accredited for the French Research Tax Credit (CIR): officially recognized by the French Ministry of Higher Education & Research to provide high-level R&D consulting services with significant fiscal advantages for clients
- Providing high-level R&D consulting and objective due diligence through a truthful examination of raw data for M&A and investment evaluations
- Deploying applied AI and Python-based pipelines to automate experimental analysis, ensuring the highest standards of research integrity for biotech clients
data analysis
biostatistics
bioinformatics
applied AI
due diligence
scientific writing
reproducible research
- Directed the preclinical lifecycle for a diverse portfolio including small molecules, peptides, and biologics
- Established GLP IND-enabling programs for lead candidates in ophthalmology and successfully extended packages to support Phase IIa trials in autoimmune and allergy indications
- Authored and defended critical regulatory documentation for the FDA, EMA, and CDE (China), including Investigator Brochures and CTD Modules
FDA/EMA/CDE
IND-enabling
PK/PD
toxicology
ocular toxicity
nonhuman primates
small molecules
peptides
inflammation
allergy
- Acted as a strategic consultant between R&D and Technical Development (PTDE), facilitating the transfer of human immunobiology techniques to support high-priority assets like gantenerumab and glofitamab
- Led the transition of artisanal cell-based assays into standardized, robotic, and GMP-compliant workflows, significantly enhancing throughput and data reproducibility
GMP bioassays
ADCC
ADCP
NK cells
macrophages
AAV
imaging cytometry
ddPCR
cell & gene therapy
Pentraxin-2
gantenerumab
pertuzumab
glofitamab
- Responsible for personalized neoantigen vaccine assembly for the NECVAXNEO1 clinical trial
- Applied machine learning for epitope assembly and neoantigen discovery using NGS-derived data
personalised medicine
NGS
neoantigen discovery
epitope assembly
machine learning
- Directed R&D and nonclinical development of the VXM oral T-cell vaccine platform (VXM01, VXM04, VXM06, VXM10)
- Spearheaded the development of a clinical-stage neoantigen asset (NECVAXNEO1) derived from a proprietary platform licensed to NEC
- Supervised GCLP immunomonitoring and histopathology for Glioblastoma (GBM) Phase I/II clinical trials while managing international CRO partnerships
- Led Business Development efforts (industry and academic collaborations)
cancer vaccines
DNA vaccine
Salmonella
glioblastoma
preclinical
toxicology
GCLP
immunomonitoring
data analysis
bioinformatics
histopathology
business development
- Dedicated period for childcare and family support
- Managed a full-scale residential renovation within a strict budget, coordinating over 10 contractors and navigating local planning approvals
- Utilized this period to advance professional competencies in physiology, biostatistics, and programming
childcare
project management
biostatistics
Python
self-education
- Assessed novel tumor stroma-targeted IL-2-variant immunocytokines, combining them with immune checkpoint inhibitors in genetically engineered mouse models (GEMM) of lung cancer (Lab: Prof. Zippelius/Dr. Klein)
- Served as Deputy Study Director for animal licenses and established high-impact collaborations with ETHZ, MGH, and CureVac
IL-2
immunocytokines
immune checkpoint inhibitors
lung cancer
GEMM
imaging (SPECT/µCT)
LTK2
study director
animal licenses
- Characterized T-cell responses in melanoma patients following therapeutic vaccination using single-cell analysis and TCR sequencing (Lab: Prof. Romero)
- Mentored and supervised undergraduate/graduate students and technical staff in advanced laboratory techniques
TCR sequencing
microarray
single-cell analysis
T-cell cloning
ELISpot
lentivirus
- Spearheaded a national initiative focused on the transduction of human dendritic cells using adenoviral vectors to enhance the presentation of HIV-1 epitopes
- Orchestrated a long-term collaborative project with the Laboratory of Virology & Viral Pathogenesis, focusing on potentiating anti-HIV-1 immune responses
HIV-1
adenovirus
dendritic cells
molecular biology
viral pathogenesis
grant management
- Innovated functional CD40L mimetics utilizing C3-symmetric peptide scaffolds, working at the high-impact interface of organic chemistry and immunology
- Served as Lab Manager within the Immunologie et Chimie Thérapeutiques group at the IBMC (Lab: Prof. Muller; Member of the French Academy of Sciences), overseeing daily operations and technical infrastructure
- Mentored and trained a diverse group of students and technical staff in advanced laboratory techniques
CD40L
peptide scaffold
apoptosis
SPR
confocal microscopy
lab management
mentoring
- Instructed B.Sc. biochemistry students in immunology laboratory practices (travaux pratiques), focusing on experimental design and data interpretation
- Prepared and taught classroom-based courses (travaux dirigés) in immunobiology for foundational biology degrees
pedagogy
immunology instruction
experimental design
scientific communication
- Provided critical technical infrastructure support for research scientists, including the deployment and optimization of scientific software and hardware
- Managed network troubleshooting and server maintenance, ensuring 24/7 data availability for high-throughput research instruments
- Conducted technical workshops for staff to improve digital literacy and software efficiency within the laboratory environment
network administration
systems maintenance
scientific software
troubleshooting
infrastructure
MULTIDISCIPLINARY METHODOLOGICAL AND COMPUTATIONAL EXPERTISE
Experimental and Translational Sciences
Immunology
human PBMC
Ficoll
serum
MACS
T-cell clones
dendritic cells
macrophages
51Cr-release
BATDA
CTL
lentivirus
pMHC multimers
ELISA
ELISpot
multiplex immunoassays
Cell biology and imaging
flow cytometry (Fortessa, Accuri, Calibur, Array, CyAn, Gallios, Attune)
imaging flow cytometry (Amnis)
FACS (Ventage, Aria)
intracellular staining
CBA
transfection
RNAi
cell cycle
apoptosis
3D-culture
confocal microscopy
live imaging
fluorescent IHC
H&E staining
cryosection
AAV
in vivo pharmacology
injection (iv, sc, po, im, id, nas)
intratracheal
GEMMs
tumor xenografts
TGI
survival
blood sampling
organ collection
lymphoid tissues
genotyping
SPECT/μCT (Bioscan)
animal licenses
Molecular biology and biochemistry
PCR
ddPCR
RT-PCR
RNA-Seq
DNA sequencing
TCR spectratyping
molecular cloning
recombinant proteins
hybridoma
Southern blotting
Northern blotting
whole genome microarray (Agilent)
SPR (BIAcore)
DLS
SDS-PAGE
Western blot
2D electrophoresis
Advanced Computational & Data Engineering
Expert in leveraging Python (Pandas, Plotly, Scikit-learn) and Cloud (GCP) to build automated discovery tools that ensure biological data integrity and research auditability. Architect of high-performance Python pipelines and version-controlled reporting workflows, moving the laboratory environment toward IT-driven reproducibility. Expert in designing (sc)RNA-Seq pipelines and NGS-based neoantigen discovery workflows.
Applied AI, data science & programming
Python (NumPy, SciPy, pandas)
matplotlib/seaborn/plotly
machine learning (scikit-learn)
applied AI (OpenAI and Gemini APIs)
R (Bioconductor)
Markdown & LaTeX
SQL
full-stack Django
HTML/CSS/JS/D3
Qt for Python (PySide6)
Bash
Powershell
C++
MATLAB
Bioinformatics, cloud & research operations
(sc)RNA-Seq pipelines
NGS-based neoantigen discovery
PyMOL
Google Cloud Platform (GCP)
Jupyter
GitLab/GitHub
Docker
OpenBIS
advanced Excel (VBA/Python)
Power BI
FlowJo
Prism
GeneSpring
Hardware & systems engineering
electronics (integrated circuits, microprocessors)
microcontrollers (Arduino, RPi)
MicroPython
Linux SysAdmin (Ubuntu, Kali)
infrastructure optimization
Professional development and strategic certifications
Cloud computing & applied AI (2023—2026)
Google Cloud Skills Boost:
Infrastructure
Cloud Fundamentals
Data Analytics
Core Infrastructure
Big Data & ML Fundamentals
AWS/Azure Professionals
Applied AI:
OpenAI Python API Bootcamp (GPT-4 Integration)
Advanced mathematics & data science (2017—2023)
Mathematics for Machine Learning (Imperial College London):
Linear Algebra
Multivariate Calculus
Principal Component Analysis
Foundation in Mathematics (Cnam, Paris)
Bayesian Estimation (Centrale Nantes)
Data Science:
Data Scientist with Python Track (DataCamp)
Machine Learning with scikit-learn (INRIA)
SQL Fundamentals (DataCamp)
IBM Data Science Professional (SQL, Visualization, Machine Learning)
Python foundations:
Python for Research (HarvardX)
Python 3 Professional (Université Côte d'Azur)
Bash Shell Mastery (Université de la Réunion)
Quantitative biology & bioinformatics (2017—2023)
Genomics:
RNA-seq Data Analysis (University of Pennsylvania)
Transcriptomics (SIB)
Bio-informatique pour la Génomique Médicale (CEA)
Genomes & Algorithms (INRIA)
Modeling & stats:
Introduction to Molecular Modeling (Schrödinger)
Quantitative Biology (MITx)
Introduction to Statistics with Python (SIB)
Introduction à la statistique avec R (Université Paris Sud)
Reproducibility:
Reproducible Research (INRIA)
Docker & Singularity (SIB)
Version Control with Git (SIB)
Scientific foundation and regulatory leadership (2004—2017)
Regulatory & management:
Accredited Study Director (LTK Module 2) (University of Zurich)
SME Instrument Training (Euresearch)
Création d'entreprises innovantes (Université de Montpellier)
Technical masterclass:
Chemistry for higher education (Université de Liège)
Human Histology (Université de Liège)
Animal Experimentation & Surgery (Université Strasbourg I)
Multicolor Cytometry (AFC Paris)
Proteomics (IBMC)
Confocal Microscopy (IBMP)
SCIENTIFIC IMPACT, PUBLICATIONS AND INTELLECTUAL PROPERTY (IP)
Demonstrated research excellence with an h-index of 19, 24 peer-reviewed publications, and 2 international patents; formally accredited for the French Research Tax Credit (CIR) 2025—2027 and officially recognized by the French Ministry of Higher Education & Research.
Publications
- Young LE, Schnieke AE, McCreath KJ, Wieckowski S, Konfortova G, Fernandes K, Ptak G, Kind AJ, Wilmut I, Loi P, Feil R. Conservation of IGF2-H19 and IGF2R imprinting in sheep: effects of somatic cell nuclear transfer. Mech Dev (2003) 120:1433-1442. doi: 10.1016/j.mod.2003.09.006
- Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP, Gennaro R, Prato M, Bianco A. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl (2005) 44:6358-6362. doi: 10.1002/anie.200501613
- Wieckowski S, Fournel S, Sun W, Trouche N, Dumortier H, Bianco A, Chaloin O, Habib M, Peter JC, Schneider P, Vray B, Toes RE, Offringa R, Melief CJ, Hoebeke J, Guichard G. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol (2005) 1:377-382. doi: 10.1038/nchembio746 – Research Highlights: Drug Discovery: Immune booster. Nature (2005) 438:132. Immunotherapy: TNFR superfamily trimers. Nat Rev Drug Discov (2006) 5:1
- Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, Prato M, Bianco A. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb) (2006) 21:1182-1184. doi: 10.1039/b516309a – Recognized as within the top 50 articles published in 2006 in Chem Commun
- Bianco A, Fournel S, Wieckowski S, Hoebeke J, Guichard G. Solid-phase synthesis of CD40L mimetics. Org Biomol Chem (2006) 4:1461-1463. doi: 10.1039/b601528j
- Kostarelos K, Lacerda L, Pastorin G, Wu W, Wieckowski S, Luangsivilay J, Godefroy S, Pantarotto D, Briand JP, Muller S, Prato M, Bianco A. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotech (2007) 2:108-113. doi: 10.1038/nnano.2006.209
- Wieckowski S, Trouche N, Chaloin O, Guichard G, Fournel S, Hoebeke J. Cooperativity in the interaction of synthetic CD40L mimetics with CD40 and its implication in cell signaling. Biochem (2007) 46:3482-3493. doi: 10.1021/bi602434a
- Habib M, Chamekh M, Rivas MN, Wieckowski S, Sun W, Bianco A, Trouche N, Chaloin O, Dumortier H, Goldman M, Guichard G, Fournel S, Vray B. Small molecule CD40L mimetics promote control of parasitemia by enhancing CD8+ cells production of interferon-γ during experimental Trypanosoma cruzi infection. J Immunol (2007) 178:6700-6704. doi: 10.4049/jimmunol.178.11.6700
- Trouche N, Wieckowski S, Sun W, Chaloin O, Briand JP, Hoebeke J, Fournel S, Guichard G. Small trivalent architectures mimicking homotrimers of the TNF superfamily member CD40L: delineating the relationship between structure and effector function. JACS (2007) 129:13480-13492. doi: 10.1021/ja073169m
- Rich LR, Papalia GA, Flynn PJ… Wieckowski S… Myszka DG. A global benchmark study using affinity-based biosensors. Anal Biochem (2009) 386:194-216. doi: 10.1016/j.ab.2008.11.021
- Partidos CD, Hoebeke J, Wieckowski S, Chaloin O, Bianco A, Moreau E, Briand JP, Desgranges C, Muller S. Immunomodulatory consequences of ODN CpG-polycation complexes. Methods (2009) 49:328-333. doi: 10.1016/j.ymeth.2009.03.005
- Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P. Tumor antigen specific regulatory CD4 T-cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res (2009) 69:8085-8093. doi: 10.1158/0008-5472.CAN-09-2226
- Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero P, Speiser DE, Rufer N. Fine structural variations of αβTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol (2009) 183:5397-5406. doi: 10.4049/jimmunol.0901460
- Iancu EM, Baumgaertner P, Wieckowski S, Speiser DE, Rufer N. Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J Biomed Biotech (2011) 2011:452606. doi: 10.1155/2011/452606
- Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplanke B, Romero P, Rufer N, Speiser DE. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest (2011) 121:2350-2360. doi: 10.1172/JCI46102
- Wieckowski S, Speiser DE, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, Michielin O, Romero R, Rufer N. Single cell analysis reveals similar functional competence of dominant and non-dominant CD8 T-cell clonotypes. Proc Natl Acad Sci USA (2011) 108:15318-15323. doi: 10.1073/pnas.1105419108
- Leimgruber A, Ferber M, Irving M, Wieckowski S, Hussain-Kahn H, Derré L, Rufer N, Zoete V, Michielin O. TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires. PloS ONE (2011) 6: e26301. doi: 10.1371/journal.pone.0026301
- Lövgren T, Baumgaertner P, Wieckowski S, Devêvre E, Guillaume P, Luescher I, Rufer N, Speiser DE. Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific T cells after vaccination with low peptide dose. Cancer Immunol Immunother (2012) 61(6):817. doi: 10.1007/s00262-011-1140-1
- Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, Speiser DE, Rufer N. Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother (2012) 35(6):488. doi: 10.1097/CJI.0b013e31826183a7
- Wieckowski S, Hemmerle T, Savic Prince S, Dolder Schlienger B, Hillinger S, Neri D, Zippelius A. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung. Lung Cancer (2015) 88(1):9. doi: 10.1016/j.lungcan.2015.01.019
- Gannon PO, Wieckowski S, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, Rufer N. Quantitative TCR avidity assessment by NTAmers reveals melanoma antigen-specific T cell repertoires enriched for high functional competence. J Immunol (2015) 195:356. doi: 10.4049/jimmunol.1403145
- Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer H, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. A phase 1 trial extension to assess immunologic efficacy and safety of prime – boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. OncoImmunology (2018) 7(4):e1303584. doi: 10.1080/2162402X.2017.1303584
- Kashyap AS, Fernandez-Rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park SM, Wieckowski S, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker HC, Zippelius A. GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses. Cell Rep (2019) 28(13):3367. doi: 10.1016/j.celrep.2019.08.057
- Wieckowski S, Avenal C, Orjalo AV, Gygax D, and Cymer F. Toward a better understanding of bioassays for the development of biopharmaceuticals by exploring the structure-antibody-dependent cellular cytotoxicity relationship in human primary cells. Front Immunol (2020) 11: 552596. doi: 10.3389/fimmu.2020.552596
Books
- Wieckowski S. Intuitive Biostatistics with Python — A Python Companion Guide for Life Science Professionals. Oxford University Press, New York (Forthcoming 2026). ISBN: 978-0-19-784502-8
Patents
- Guichard G, Fournel S, Chaloin O, Trouche N, Wieckowski S, Hoebeke J. Novel multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs. Brevet Français 04/13331, déposant CNRS (15/12/2004). International Application PCT/FR2005/03146 (15/12/2005). International Publication WO/2006/064133 (22/06/2006)
- Guichard G, Fournel S, Trouche N, Wieckowski S. Novel multimeric molecules, a process for preparing the same and the use thereof for manufacturing medical drugs. Brevet Français 07/00809, déposant CNRS (05/02/2007). International Application PCT/FR2008/000129 (04/02/2008). International Publication WO/2008/110695 (18/09/2008)
Communications (selection)
- Wieckowski S, Avenal C, Orjalo AV, Gygax D, and Cymer F. A better understanding of bioassays – comparison of binding assays, reporter gene assays and primary cell-based assays of glycoengineered monoclonal antibodies. BEBPA’s Virtual 2021 EUR Bioassay Conference. Oral presentation
- Wieckowski S, Podola L, Kobl I, Smetak H, Springer M, Nugues AL, Slos P, Broadmeadow A, Chesher C, Adda Berkane A, Wei M, Breiner K, Meichle A, Breiner K, Mansour M, Beckhove P, Lubenau H. Modulating T cell immunity in tumors by targeting tumor-associated antigens, PD-L1 and neoantigens using a versatile live attenuated oral Salmonella DNA vaccination platform. AACR Annual Meeting, Chicago, 2018. Poster 733
- Wieckowski S. Non-clinical safety, immunogenicity and antitumor efficacy of live attenuated Salmonella Typhimurium based oral T-cell vaccines. ASGCT 20th Annual Meeting, Washington DC, 2017. Oral presentation
- Wieckowski S, Podola L, Springer M, Broadmeadow A, Stevens P, Chesher C, Adda Berkane A, Wei M, Kobl I, Meichle A, Beckhove P, Breiner K, Lubenau H. Non-clinical safety, immunogenicity and antitumor efficacy of live attenuated Salmonella Typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. AACR Annual Meeting, Washington DC, 2017. Poster 4558
- Wieckowski S. Using the immune system to treat cancer – Could we cure cancer in the next ten years? European Health Science Match. Heidelberg, 2016. Oral presentation
- Wieckowski S. Therapeutic synergism of a novel tumor stroma-targeted IL-2-variant immunocytokine with standard-of- care anti-cancer therapeutics and immunomodulatory antibodies in the genetically engineered KP mouse model of non-small cell lung cancer. Roche Symposium of the Roche Postdoc Fellowship Program. Basel, 2013. Oral presentation
- Wieckowski S, Müller P, Freimoser-Grundschober A, Savic S, Fink Y, Karanikas V, Umana P, Pisa P, Klein C, Zippelius A. Therapeutic synergism of a novel tumor stroma-targeted IL-2-variant immunocytokine with standard-of-care anti-cancer therapeutics and immunomodulatory antibodies in the genetically engineered KP mouse model of non-small cell lung cancer. Roche Symposium of the Roche Postdoc Fellowship Program. Penzberg, 2012. Poster RPF ID 216
- Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. Characterization of CD8+ T cell responses induced by vaccination with Melan-A peptides in melanoma patients. Role of Inflammation in Oncogenesis and Immune Escape in Cancer joint Keystone Symposia, Keystone, CO, 2010. Poster J5-338
- Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. Molecular characterization of CD8+ T cell responses in melanoma patients following therapeutic peptide vaccination. 4e Journée Scientifiques du Cancéropôle Lyon Auvergne Rhône-Alpes, Archamps (France), 2009. Poster P70. Best Poster Award
- Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. CD8 T cell responses in melanoma patients following therapeutic peptide vaccination. 1st Swiss Immunotherapy Symposium, Lausanne, 2009. Oral presentation
- Wieckowski S, Trouche N, Hoebeke J, Guichard G, Fournel S. Application of functional small synthetic CD40L mimetics to lymphoma therapy. 1st joint meeting of European National Societies of Immunology, 16th European Congress of Immunology. Paris, 2006. Poster PD-3918
- Wieckowski S, Trouche N, Sun W, Chaloin O, Hoebeke J, Guichard G, Fournel S. Improvements of small synthetic CD40L mimetics and their effects on cell signaling. MipTec – the 9th Leading European Drug Discovery Event. Basel, 2006. Poster P89
- Wieckowski S, Trouche N, Chaloin O, Bianco A, Hoebeke J, Dumortier H, Guichard G, Fournel S. A synthetic multimeric ligand of CD40 is able to mimic effector functions of the natural CD40L. Congrès Annuel de la Société Française d’Immunologie. Paris, 2004. Poster P50
Congress Abstracts
- Wieckowski S, Podola L, Smetak H, Nugues AL, Slos P, Berkane AA, Wei M, Breiner K, Meichle A, Beckhove P, Mansour M, Lubenau H. Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform. Cancer Res (2018) 78(13 Supplement):733-733
- Wick W, Wick A, Sahm F, Riehl D, von Deimling A, Bendszus M, Kickingereder P, Bonekamp D, Beckhove P, Schmitz-Winnenthal FH, Jungk C, Wieckowski S, Podola L, Herold-Mende C, Unterberg A, Platten MJ. VXM01 phase I study in patients with progressive glioblastoma: Final results. J Clin Oncol (2018) 36(15_suppl):2017-2017
- Wieckowski S, Smetak H, Kobl I, Podola L, Nugues AL, Slos P, Berkane AA, Wei M, Breiner K, Meichle A, Mansour M, Schroff M, Beckhove P, Lubenau H. Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1. J Clin Oncol (2018) 36(5_suppl):74-74
- Wieckowski S, Podola L, Springer M, Kobl I, Koob Z, Mignard C, Berkane AA, Wei M, Meichle A, Breiner K, Schroff M, Beckhove P, Lubenau H. Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. Cancer Res (2017) 77(13S):Abstract nr 4558
- Wick W, Wick A, Nowosielski M, Sahm F, Riehl D, Arzt M, von Deimling A, Bendszus M, Kickingereder P, Bonekamp D, Beckhove P, Schmitz-Winnenthal FH, Jungk C, Wieckowski S, Herold-Mende C, Lubenau H, Unterberg A, Platten MJ. VXM01 phase I study in patients with resectable progression of a glioblastoma. J Clin Oncol (2017) 35(15_suppl):2061-2061
- Wieckowski S, Springer M, Podola L, Broadmeadow A, Stevens P, Chesher CJ, Berkane AA, Wei M, Meichle A, Beckhove P, Breiner K, Lubenau H. Non-clinical safety and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. Eur J Cancer (2016) 69:S106
- Guichard G, Trouche N, Wieckowski S, Sun W, Chaloin O, Bianco A, Hoebeke J, Schneider P, Fournel S. Rationally designed multivalent architectures for mimicking homotrimers of CD40L, a member of the TNF superfamily. Peptides for Youth: The Proceedings of the 20th American Peptide Symposium, Montreal (Canada), 2007. Adv Exp Med Biol (2009) 611:355-357
Peer-Reviewing Authority
Active reviewer for Journal for ImmunoTherapy of Cancer, Cancer Immunology Immunotherapy, Journal of Cancer Research and Clinical Oncology, Cancers, Vaccines, Viruses, Biomedicines, Immuno, Journal of Clinical Medicine, Marine Drugs, Genes, Biomolecules, and International Journal of Molecular Sciences.
Detailed records available via Web of Science and ORCID.
Detailed records available via Web of Science and ORCID.
Grants & Fellowships
- Freiwillige Akademische Gesellschaft (FAG) Grant (2013)
- Roche Postdoctoral Fellowship (RPF) Extension (2013)
- Wilhelm Sander-Stiftung Fellowship (2010)
- ANRS Research Grant & Post-doctoral Fellowship (2007)
- Fondation pour la Recherche Médicale (FRM) Fellowship (2007)